Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by TIAA Trust National Association

TIAA Trust National Association cut its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 24,561 shares of the biopharmaceutical company’s stock after selling 479 shares during the period. TIAA Trust National Association’s holdings in Gilead Sciences were worth $2,269,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. TD Asset Management Inc. grew its position in Gilead Sciences by 40.2% in the 4th quarter. TD Asset Management Inc. now owns 1,092,705 shares of the biopharmaceutical company’s stock valued at $100,933,000 after buying an additional 313,259 shares during the last quarter. Modern Wealth Management LLC boosted its holdings in shares of Gilead Sciences by 84.8% in the fourth quarter. Modern Wealth Management LLC now owns 5,764 shares of the biopharmaceutical company’s stock valued at $550,000 after acquiring an additional 2,645 shares in the last quarter. CoreFirst Bank & Trust acquired a new position in shares of Gilead Sciences during the fourth quarter worth about $83,000. Lynx Investment Advisory raised its holdings in Gilead Sciences by 3.6% during the fourth quarter. Lynx Investment Advisory now owns 8,501 shares of the biopharmaceutical company’s stock worth $785,000 after purchasing an additional 296 shares in the last quarter. Finally, Crowley Wealth Management Inc. acquired a new stake in Gilead Sciences in the fourth quarter valued at about $229,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

GILD has been the topic of several recent analyst reports. DZ Bank upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 target price on the stock in a research report on Thursday, February 13th. Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a “hold” rating to a “buy” rating and increased their price objective for the stock from $80.00 to $120.00 in a research report on Tuesday, February 18th. Wells Fargo & Company boosted their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. The Goldman Sachs Group increased their price target on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a “neutral” rating in a report on Wednesday, February 12th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Gilead Sciences from $105.00 to $115.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $104.52.

Gilead Sciences Trading Up 1.3 %

Shares of GILD opened at $109.27 on Thursday. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96. The company has a market capitalization of $136.08 billion, a PE ratio of 295.32, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. The stock has a fifty day moving average of $104.69 and a two-hundred day moving average of $94.46. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.89%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences’s payout ratio is presently 854.05%.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the transaction, the chief financial officer now owns 129,873 shares in the company, valued at approximately $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders sold 302,785 shares of company stock valued at $30,503,250. Insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.